Bookmark
Forward
Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply.
JAMA oncology 2020 Apr 01Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Feng Wang, Qi Zhao, Rui-Hua Xu. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply. JAMA oncology. 2020 Apr 01;6(4):590
Mesh Tags
Substances
PMID: 32134432
View Full Text
